Protein Sequencing Market, By Technology (Edman Degradation, Mass Spectrometry, Others), By Product (Instruments, Reagents, Kits & Consumables, Software & Services), By Application (Academic Research, Clinical Diagnosis, Biopharmaceuticals, Others), By End User (Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, Contract Research Organizations), By Region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa)

Published In : Dec 2023

Code : CMI6507

Pages :140

Formats :

Excel and PDF

Industry : Biotechnology

Market News

Recent Developments:

New product launches:

On June 05, 2023, Bruker Corporation, an American manufacturer of scientific instruments announced transformative sensitivity on the 4D-Proteomics timsTOF platform with the launch of the new timsTOF Ultra mass spectrometer. It incorporates a new Captive Spray Ionization (CSI) Ultra ion source with larger capillary and optimized vortex gas flow, a novel 4th-generation TIMS (trapped ion mobility separation) XR cell and 14bit digitizer.
In December 2022, Quantum-Si Incorporated, a protein sequencing company, announced the commercial availability of Platinum, the world’s first next-generation single-molecule protein sequencing platform
In June 2020, Agilent Technologies, a global company announced that the company has introduced 6560 Ion Mobility Q-TOF LC/MS system for biopharma applications. It enables enhanced protein characterization.

Acquisition and partnerships:

On October 17 2023, Thermo Fisher Scientific Inc., the world leader in serving science, and Olink Holding AB, a leading provider of next-generation proteomics solutions, announced that their respective boards of directors have approved Thermo Fisher’s proposal to acquire Olink for US$ 26.00 per common share in cash, representing US$ 26.00 per American Depositary Share (ADS) in cash.
On January 05, 2023, QIAGEN, a provider of molecular testing solutions announced an exclusive strategic partnership with California-based population genomics leader Helix to advance companion diagnostics for hereditary diseases. Under the agreement, QIAGEN will be the exclusive marketing and contracting partner in the U.S. for Helix’s companion diagnostic services. The partnership will leverage the Helix® Laboratory Platform, which was granted the first-ever U.S. Food & Drug Administration de novo class II authorization for a whole exome sequencing platform.
In January 2022, Illumina, Inc., a biotechnology company announced it has entered into a definitive co-development agreement with SomaLogic to bring the SomaScan Proteomics Assay onto Illumina's current and future high throughput next-generation sequencing (NGS) platforms. This partnership accelerates the rapidly growing high throughput sector of the proteomics market. With the scale and speed of Illumina NGS technology, researchers can more effectively and efficiently make biological connections from genetic sequence (genotype) to cellular function (phenotype) and accelerate opportunities for clinical impact.